Animals. Fmr1 knockout mice in a FVB background (FVB.129P2-Pde6b + Tyr c−ch Fmr1 tm1Cgr /J) and WT mice (FVB.129P2-Pde6b + Tyr c−ch /AntJ) were purchased from The Jackson Laboratory and crossed to obtain Fmr1 −/y and WT littermates. Fmr1 knockout mice in a C57BL/6J congenic background (B6.129P2-Fmr1 tm1Cgr /J) 4 were obtained from the Baylor College of Medicine Mouse Facility. Double-mutant mice (Fmr1 −/y Cnr1 +/− ) in a C57BL/6J background were initially generated by crossing homozygous female mice carrying the Fmr1 mutation (Fmr1 −/− ) with homozygous male mice carrying the Cnr1 mutation (Cnr1 −/− ). Subsequently, mice used for experimentation were derived from the crossing of female Fmr1 +/− Cnr1 +/+ mice with male Fmr1 +/y Cnr1 +/− mice. All experimental mice were bred in house at the Barcelona Biomedical Research Park (PRBB) Animal Facility. Fmr1 −/y and WT mice were used at 12-16 weeks of age, except for in the study of audiogenic seizure susceptibility (where mice were 21-23 d old). Mice were housed four per cage in a temperature-controlled (21 °C ± 1 °C) (mean ± range) and humidity-controlled (55% ± 10%) environment. Food and water were available ad libitum. All the experiments were performed during the light phase of a 12 h light, 12 h dark cycle (lights on at 8 a.m. and off at 8 p.m.). Mice were handled for 1 week before starting the experiments. Only male mice were used. All animal procedures followed standard ethical guidelines (European Communities Directive 86/60-EEC) and were approved by the local ethical committee
l e t t e r S Fragile X syndrome (FXS), the most common monogenic cause of inherited intellectual disability and autism 1 , is caused by the silencing of the FMR1 gene, leading to the loss of fragile X mental retardation protein (FMRP) 2 , a synaptically expressed RNA-binding protein regulating translation 3 . The Fmr1 knockout model recapitulates the main traits of the disease 4 . Uncontrolled activity of metabotropic glutamate receptor 5 (mGluR5) 5, 6 and mammalian target of rapamycin (mTOR) signaling [7] [8] [9] seem crucial in the pathophysiology of this disease. The endocannabinoid system (ECS) is a key modulator of synaptic plasticity, cognitive performance, anxiety, nociception and seizure susceptibility 10 , all of which are affected in FXS. The ECS receptors, CB1 (CB1R) and CB2 (CB2R), are activated by phospholipid-derived endocannabinoids. Synaptic activation of mGluR5 initiates the synthesis of endocannabinoids 10, 11 and promotes CB1R-driven long-term depression of synaptic strength 10 . Notably, mGluR5 activation is altered in several brain areas of Fmr1 knockout mice [12] [13] [14] . We found that CB1R blockade in male Fmr1 knockout (Fmr1 −/y ) mice through pharmacological and genetic approaches normalized cognitive impairment, nociceptive desensitization, susceptibility to audiogenic seizures, overactivated mTOR signaling and altered spine morphology, whereas pharmacological blockade of CB2R normalized anxiolytic-like behavior. Some of these traits were also reversed by pharmacological inhibition of mTOR or mGluR5. Thus, blockade of ECS is a potential therapeutic approach to normalize specific alterations in FXS.
FXS, the principal monogenic syndrome leading to inherited intellectual disability and autism 15 , is caused by an unstable expansion of CGG repeats in the 5′ untranslated region of the gene FMR1, producing loss of expression of FMRP (ref. 2) . Different factors, including uncontrolled activity of group I metabotropic glutamate receptors, mainly mGluR5 5, 6 , reduced GABAergic transmission 16, 17 and enhanced mTOR signaling 7 , seem to have causal roles in FXS deficits.
Synaptic activation of mGluR5 promotes the synthesis of endocannabinoids 11 , triggering CB1R-mediated long-term depression (LTD) of excitatory and inhibitory transmission 10 . Notably, deregulated mGluR5-driven LTD has been recently described in several brain areas of adult Fmr1 −/y mice [12] [13] [14] . At the molecular level, ECS activation enhances the phosphatidylinositol-3-kinase (PI3K)-protein kinase B (Akt)-mTOR-p70S6 kinase (p70S6K) signaling pathway in the hippocampus 18, 19 . This transduction pathway is closely related to synaptic plasticity 20 , is deregulated in Fmr1 −/y mice 7 and mediates particular behavioral effects of cannabinoids 21 , but its pharmacological inhibition has not previously been tested in Fmr1 knockout mice. Because the ECS has a putative regulatory capacity on most FXS traits, such as cognition, anxiety-like behavior, antinociception and neuronal plasticity 10 , we sought to characterize the ECS-mTOR pathway as a potential target for therapeutic intervention in FXS.
We found that acute administration of the CB1R antagonist rimonabant in Fmr1 −/y mice during the consolidation phase of the objectrecognition memory test ameliorated their cognitive deficit without affecting the performance of wild-type (WT) littermates (Fig. 1a) or total exploration time (Supplementary Fig. 1 ). Under similar conditions, acute blockade of CB2R with AM630 or of mGluR5 with MTEP were not effective (Fig. 1b,c) . Notably, acute administration of the specific mTOR inhibitor temsirolimus prevented memory impairment (Fig. 1d) .
When chronically administered, rimonabant, MTEP and temsirolimus, but not AM630, were equally effective at preventing the cognitive deficit in Fmr1 −/y mice ( Fig. 1e-h) . Notably, acute intrahippocampal microinjection of rimonabant during object-recognition memory consolidation improved the cognitive deficit in Fmr1 −/y mice ( Fig. 1i and Supplementary Fig. 2 ), pointing to the crucial role of CB1R activity in this brain region in the memory deficit. We next Targeting the endocannabinoid system in the treatment of fragile X syndrome l e t t e r S 6 0 4 VOLUME 19 | NUMBER 5 | MAY 2013 nature medicine tested whether mGluR5 and CB1R inhibition converge to normalize the cognitive deficit. MTEP has a short half-life 6 and was only effective after chronic administration. Therefore, we treated mice chronically with a suboptimal dose of MTEP (5 mg per kg body weight) and administered an acute dose of rimonabant after the training session. We found that mice that received the combined treatment had enhanced performance compared with those that received both treatments separately (Fig. 1j) , pointing to a complementary involvement of both mechanisms. Recent studies have proposed that Fmrp loss affects the efficacy of mGluR5-driven endocannabinoid production machinery in different brain areas [12] [13] [14] . Under our experimental conditions, we did not detect differences between WT and Fmr1 −/y mice in brain basal amounts of the two main endocannabinoids, 2-arachidonoylglycerol (WT, 100.0% ± 5.7% (mean ± s.e.m.); Fmr1 −/y , 109.7% (as compared to WT) ± 4.8%; P = 0.213) and anandamide (WT, 100% ± 4.9%; Fmr1 −/y , 107.4% ± 3.0%; P = 0.223), or in the hippocampal expression of several components of the ECS (Supplementary Fig. 3 ), in agreement with previous studies 12, 13 . We next examined CB1R-dependent modulation of GABAergic transmission in the hippocampus CA1 area. To estimate possible differences in synaptic endocannabinoid tone, we analyzed the effect of pharmacological CB1R blockade on baseline inhibitory postsynaptic currents (IPSCs) in hippocampal slices from WT and Fmr1 −/y mice 22 . Bath application of rimonabant increased IPSC amplitude to a similar extent in WT and Fmr1 −/y mice ( Supplementary Fig. 4a ), suggesting that Fmrp loss does not affect the amount of tonic CB1R activation at GABAergic synapses. Moreover, inhibitory LTD (i-LTD) initiated by mGluR1 and mGluR5 (ref. 10 ), a form of synaptic plasticity mediated by endocannabinoids, was similarly induced by high-frequency stimulation (HFS) and theta-burst stimulation (TBS) in both WT and Fmr1 −/y mice (Fig. 2a,b) . Consistently, we detected no differences between WT and Fmr1 −/y mice in the magnitude of i-LTD elicited by bath application of the mGluR1 and mGluR5 agonist DHPG or in the ability of the CB1R agonist CP55,940 to inhibit GABAergic transmission onto CA1 neurons ( Supplementary Fig. 4 ). All of these data suggest that Fmrp removal does not substantially affect the ECS modulation of inhibitory transmission and long-term synaptic plasticity in the hippocampal CA1 area.
The hippocampus of Fmr1 −/y mice showed a marked increase in the phosphorylation of p70S6K (Thr389) (Fig. 2c ) that localized to CA1 pyramidal neurons but not GABAergic interneurons (Fig. 2d) . Remarkably, the phosphorylation status of p70S6K (Thr389) and Akt (Ser473), both of which are involved in mTOR pathway signaling, was specifically enhanced in the hippocampus of Fmr1 −/y mice ( Fig. 2e and Supplementary Fig. 5 ). Chronic treatment with either rimonabant or MTEP normalized the phosphorylation of Akt (Ser473) and p70S6K (Thr389) (Fig. 2e) in hippocampal tissue. Moreover, as observed in patients with FXS 1 , Fmr1 −/y mice showed an enhanced dendritic spine density of CA1 pyramidal neurons that was also normalized by chronic rimonabant treatment (Fig. 2f) . When we classified spines on the basis of their morphology, rimonabant-treated Fmr1 −/y mice showed a decrease in thin and stubby (immature) spines and an increase in mushroom and wide (mature) spines compared to vehicle-treated Fmr1 −/y mice ( Fig. 2g) , similar to other normalizing interventions 6, 9 .
Chronic treatment with MTEP or rimonabant normalized both the cognitive deficit and the hippocampal mTOR signaling pathway in adult Fmr1 −/y mice and showed an additive effect when both treatments were combined, revealing the importance of ECS tone and mTOR activity in this cognitive deficit. mTOR signaling is crucial in memory consolidation 23 , and genetic regulation of this signaling pathway in Fmr1 −/y mice prevents some of the Fmr1 −/y features 9 , such as the elevated phosphorylation of translational control molecules, exaggerated protein synthesis, enhanced mGluR-dependent LTD, weight gain, macro-orchidism, immature dendritic spine morphology and behavioral phenotypes, including social interaction deficits, impaired novel object recognition and behavioral inflexibility. We previously showed that mTOR overactivation in CA1 pyramidal neurons is directly involved in the cognitive deficit induced by ECS activation 18, 19, 21 , which can explain the efficacy of rimonabant-mediated CB1R blockade in reversing cognitive impairment in Fmr1 −/y mice. The fact that temsirolimus also prevented the object-recognition memory deficit in Fmr1 −/y mice reinforces the concept that overactivation of mTOR signaling has a key role in this deficiency 24 and demonstrates the possibility of using these pharmacological approaches as therapy for this disease. Given that CA1 hippocampal GABAergic presynaptic membranes show 10-to 20-fold higher expression of CB1R than do glutamatergic presynaptic membranes 25 , rimonabant might help normalize the balance between excitatory and inhibitory input, which is altered in FXS, and lead to an improved output in the cognitive test by facilitating inhibitory transmission onto CA1 pyramidal cells 26 ( Supplementary  Fig. 4) . The balancing effect of rimonabant may also fit with the effect of other therapeutic approaches that aim to re-establish the excitatory-inhibitory balance, such as the mGluR5 antagonist CTEP 6 or the N-methyl-d-aspartate (NMDA) receptor antagonist memantine 27 , both of which reduce the excitatory drive, and the GABA B receptor agonist arbaclofen 17 , which increases the inhibitory drive. Adult Fmr1 −/y mice show a reduced-anxiety phenotype in the elevated plus maze (Fig. 3a-d and Supplementary Fig. 6 ) that is reminiscent of the alterations in anxiety observed in patients with FXS 15 . This trait was insensitive to rimonabant or temsirolimus (Fig. 3a,d) . 
Fmr1
-/y (n = 6) (e) Phosphorylation of p70S6K (Thr389) and Akt (pAkt) (Ser473) in hippocampal samples from WT and Fmr1 −/y mice (n = 6 mice per group). Data are shown as the mean ± s.e.m. **P < 0.01, ***P < 0.001 (Fmr1 −/y compared to WT); # P < 0.05 (treatment compared to vehicle). Statistical significance was calculated by two-tailed t test. Veh, vehicle; RIM, rimonabant; GAPDH, glyceraldehyde-3-phosphate dehydrogenase. (f) Representative DiOlistics staining of hippocampal dendrites in the CA1 field of the hippocampus and overall dendritic spine counts after pharmacological treatments. Scale bar, 2 µm. Data are shown as the mean ± s.e.m. *P < 0.05 (Fmr1 −/y compared to WT) calculated by one-way ANOVA with Dunnett's post hoc test.
(g) Morphological analysis of dendritic spines in the CA1 field of the hippocampus after pharmacological treatments. Data are shown as the mean ± s.e.m. *P < 0.05, **P < 0.01, ***P < 0.001 (Fmr1 −/y compared to WT); # P < 0.05, ## P < 0.01, ### P < 0.001 (rimonabant compared to vehicle). Statistical significance was calculated by one-way ANOVA with Dunnett's post hoc test.
npg l e t t e r S However, acute CB2R and mGluR5 blockade (Fig. 3b,c) normalized this phenotype without modifying anxiety-like behavior in WT mice (Fig. 3b,c) . In this regard, CB2R has been involved in the anxiolyticlike effects produced by an enhanced amount of 2-arachidonoylglycerol 18 , whereas CB1R has been associated with the anxiolytic-like effect of anandamide accumulation 18 . Because we used doses of rimonabant and AM630 that did not affect the anxiety-like behavior in WT mice, we conclude that the reduced-anxiety phenotype in Fmr1 −/y mice may specifically involve CB2R signaling. We used the formalin test to study another characteristic of adult Fmr1 −/y mice: diminished responses to inflammatory pain, which are sensitive to mGluR5 blockade 28 . This phenotype could be relevant to the self-injurious behavior that is often present in patients with FXS and was only normalized by rimonabant (Fig. 3e) , consistent with previous findings reported in a different model of peripheral and central nociceptive sensitization 29 .
In addition, the marked sensitivity to audiogenic seizures in Fmr1 −/y mice 30 , evoking the enhanced susceptibility of patients with FXS to epilepsy 5 , was bluntly decreased by pretreatment with rimonabant, AM630 or temsirolimus (Fig. 3f) , consistent with results previously reported using mGluR5 antagonism 6 . The involvement of CB2R and mTOR signaling in this phenotypic characteristic reveals a new central effect of these targets.
To further support the contribution of CB1R signaling in behavioral and biochemical manifestations of FXS, we generated a double-mutant Fmr1 knockout line with a reduced expression of CB1R (Cnr1 +/− ). We found that rimonabant-sensitive features in Fmr1 −/y mice, such as the cognitive deficit ( Fig. 4a and Supplementary Fig. 7 ), nociceptive desensitization (Fig. 4b) , audiogenic seizure susceptibility (Fig. 4c) and overactivation of the mTOR signaling pathway (Fig. 4d) , were blunted by the genetic decrease in CB1R expression.
Taken together, our results reveal the involvement of the ECS in specific behavioral, synaptic and molecular manifestations of FXS. We demonstrate that pharmacological or genetic blockade of CB1R normalizes some traits of FXS, such as cognitive impairment, decreased nociceptive response, increased susceptibility to audiogenic seizures and overactivation of the mTOR pathway in the hippocampus. Moreover, CB2R has an important role in the regulation of anxiolytic-like behavior and increased susceptibility to audiogenic seizures. In conclusion, our data point to regulation of the ECS and mTOR pathway as a potential target for the development of new therapeutic approaches in FXS (Supplementary Fig. 8 ).
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Methods and any associated references are available in the online version of the paper. 
